One of the companies followed here at the Canadian Penny Stocks blog is Stem Cell Therapeutics (SSS.V).  They have recently announced their year end and here are few keys takeaways and what the management had to say:

Operating Highlights from 2009 and the period ending April 13, 2010:

  • Presented positive final results for the BETAS Phase IIa clinical safety study in stroke in February 2009, including all U.S. and Canadian patient data
  • Received FDA approval to proceed with the modified REGENESIS Phase IIb acute ischemic stroke trial
  • Initiated and began enrolling patients in India and Canada for the modified REGENESIS Phase IIb acute ischemic stroke trial
  • Completed enrollment in modified REGENESIS Phase IIb acute ischemic stroke study; Q1 10

2010 Objectives

  • Report Top-line REGENESIS Phase IIb data; Q2 10
  • Complete preclinical study for hemorrhagic stroke; H2 10
  • Complete ‘end of Phase II’ meeting with FDA; H2 10
  • Initiate and enroll patients in a Phase IIa TBI clinical study; H1 10
  • Initiate MS clinical Proof-of-Concept study; H2 10
“2009 was a game-changing year for us as a Company. Working with the FDA and Health Canada to lift the clinical hold and then completing enrollment in the key phase IIb modified REGENESIS study were major accomplishments putting the Company in a strong position heading into 2010.
Additionally, the commitment that senior management showed to the Company in 2009, through their salary reductions and deferring any bonus payments, has resulted in us maintaining a strong financial position to complete our work in 2010.”
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The Company’s programs aim to repair neurological function lost due to disease or injury. SCT’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.

“2009 was a game-changing year for us as a Company. Working with the FDA and Health Canada to lift the clinical hold and then completing enrollment in the key phase IIb modified REGENESIS study were major accomplishments putting the Company in a strong position heading into 2010.


Additionally, the commitment that senior management showed to the Company in 2009, through their salary reductions and deferring any bonus payments, has resulted in us maintaining a strong financial position to complete our work in 2010.”


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The Company’s programs aim to repair neurological function lost due to disease or injury. SCT’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.

source

Technorati Tags: canadian penny stock, penny stock news, penny stocks